The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT06117137
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT06117137
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT06117137. Randomized; no masking; primary purpose treatment. Start 2023-11-15 (actual); primary completion 2025-01-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
- Condition
- Fatty Liver, Nonalcoholic
- Intervention (Drug)
- SGLT2 inhibitor
- Lead sponsor
- Sohag University
Record details
- Record id
cardio:ct-nct06117137- Content hash
b9a11351545785c1442731f7be7978cb3b9f0ad62b9a4fc76e721cf4a1fb5361